In addition, several pre-clinical tests, including a novel ex vivo organotypic tumor spheroid culture system and multiple in vivo murine syngeneic models, has shown that CDK4/6 inhibition augments the response to PD-1 blockade, thereby providing a rationale for combining CDK4/6i and ICI [31]. The gene discussed is CDK4; the disease is neoplasm.